Galderma Group N (GALD.SW)

Galderma Group N stock price today, ATLAS forecast and fair value

Healthcare · Drug Manufacturers - Specialty & Generic · SIX Swiss Exchange · Switzerland

CHF 190.90▼ -0.08%

Prices as of Oct 26, 2026 · CHF

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

51%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Galderma Group N in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Galderma Group N

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Galderma Group N a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between CHF 181.87 and CHF 201.27; in 9 out of 10, between CHF 166.24 and CHF 220.19. Estimated annual volatility is 28%.

Price, last 12 months (weekly close)

Key numbers

Market cap: CHF 40.1B
Market cap (USD): $48.4B
P/E ratio: 60.3
Dividend yield: 0.25%
52-week high: CHF 193.90
52-week low: CHF 136.30
Revenue (12 months): $5.9B
Gross margin: 69.4%
Operating margin: 20.2%
Net margin: 14.6%
Beta: -0.05

What this means

ATLAS does not publish a fair value for GALD.SW right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks GALD.SW has traded between CHF 136.30 and CHF 193.90. Today it is 1.6% below that high and 40% above its low.

On the business: net margin is 14.6%; it trades at 60.3 times earnings.

Its beta is -0.05: it tends to move less than the market.

About the company

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology.

Want to see everything about Galderma Group N?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Galderma Group N do?

What is the chance GALD.SW goes up next month?

51%: close to a coin flip. In half of the simulated outcomes, GALD.SW ends the month between CHF 181.87 and CHF 201.27.

How big is Galderma Group N and what is its P/E ratio?

Galderma Group N's market capitalization is CHF 40.1B. Its price-to-earnings (P/E) ratio is 60.3: you pay CHF 60.3 for each CHF 1.00 of yearly earnings.

Does Galderma Group N pay a dividend?

Yes. GALD.SW's current dividend yield is 0.25% at today's price (CHF 190.90).

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer